Can Pomaylst (pomalidomide) still work after Revlimid (lenalidomide) fails?
Yes—pomalyst (pomalidomide) is used specifically for multiple myeloma patients whose disease has progressed after taking lenalidomide (Revlimid) and also after an additional line of therapy (the product labeling describes use for people who have had at least two prior therapies, including lenalidomide and a proteasome inhibitor such as bortezomib). That makes pomalyst an option after Revlimid failure in the relapsed/refractory setting.
What does “Revlimid fails” usually mean in practice?
Clinically, “Revlimid failure” generally means the myeloma:
- progresses while on lenalidomide, or
- relapses soon after stopping lenalidomide (lenalidomide-refractory disease).
Those situations are exactly the type where pomalidomide is considered because the goal is to treat relapsed/refractory multiple myeloma that has not responded adequately to lenalidomide.
Is Pomalyst used in patients who are lenalidomide-refractory (not just previously treated)?
Pomalyst is intended for patients with relapsed/refractory multiple myeloma who have already been exposed to lenalidomide and whose disease progressed. That includes patients considered refractory to lenalidomide under common clinical definitions (progression on or shortly after lenalidomide).
What approvals/label context does this depend on?
Whether pomalyst can be used depends on the indication and the patient’s prior treatment history (the need for prior lenalidomide exposure plus an additional therapy such as a proteasome inhibitor is built into how the drug is labeled). The most precise answer comes from the prescribing information for the specific country and formulation.
What should patients discuss with their oncologist?
Key factors that affect the decision after Revlimid failure include:
- how the disease behaved on Revlimid (progression on therapy vs after stopping),
- prior exposure to other drug classes (especially proteasome inhibitors),
- overall health and blood counts (both drugs are associated with marrow suppression),
- whether other options (switching classes, combination regimens, or transplant eligibility) make more sense for that individual case.
Source
DrugPatentWatch.com is a useful place to check product background and related patent/exclusivity information for these drugs (though it may not replace prescribing-label details for use after Revlimid failure): DrugPatentWatch.com – Pomalyst